Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TLSI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
16 hours ago
businesswire.com
16 hours ago
zacks.com
18 hours ago
seekingalpha.com
20 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.13
vs -0.26
Q4.23
N/A
-3.78
vs -0.76
Q1.24
N/A
-1.56
vs -0.51
Q2.24
N/A
-0.21
vs -1.73
Q3.24
N/A
-0.40
vs -0.13
Q4.24
N/A
-0.35
vs -3.78
Q1.25
N/A
-0.33
vs -1.56
Q2.25
N/A
-0.27
vs -0.21
Q3.25
N/A
-0.14
vs -0.40
Q4.25
N/A
-0.10
vs -0.35
Sales Growth
YoY
Current
Estimates
Q3.23
+32%
5.2M vs 3.9M
Q4.23
+77%
5.7M vs 3.2M
Q1.24
+116%
6.5M vs 3M
Q2.24
+60%
7.4M vs 4.6M
Q3.24
+42%
7.3M vs 5.2M
Q4.24
+44%
8.3M vs 5.7M
Q1.25
+42%
9.2M vs 6.5M
Q2.25
+52%
11.2M vs 7.4M
Q3.25
+59%
11.7M vs 7.3M
Q4.25
+59%
13.2M vs 8.3M
Return on Equity
QoQ
Q1.23
+4%
0.04
vs 0.13
Q2.23
+7%
0.07
vs 0.04
Q3.23
-15%
-0.15
vs 0.07
Q4.23
+137%
1.37
vs -0.15
Q1.24
+38%
0.38
vs 1.37
Q2.24
+18%
0.18
vs 0.38
Q3.24
+12%
0.12
vs 0.18
Q4.24
+39%
0.39
vs 0.12
Q1.25
+30%
0.3
vs 0.39
Q2.25
+46%
0.46
vs 0.3
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
9
9
vs NA
NA
Q4.23
19
19
vs 9
111%
Q1.24
25
25
vs 19
32%
Q2.24
27
27
vs 25
8%
Q3.24
31
31
vs 27
15%
Q4.24
27
27
vs 31
-13%
Q1.25
33
33
vs 27
22%
Q2.25
47
47
vs 33
42%
Forecast
522%2026-Revenue
55%2026-EPS
-940%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2024-09-16
Now: Outperform
Quote Panel
Key Metrics
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.31 ( 6.81%)
After-hours 4.77$-0.09 (-1.85%)
Relative Strenght
13
Volume Buzz
23%
Earning Acce
Yes
Dist 52w H.
19%Relative Strength
TLSI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How TLSI compares to sector?
TLSI
-5x